Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
5 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Seagen Inc.
< Previous
1
2
3
Next >
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
April 13, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
April 08, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
April 08, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
April 07, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
March 16, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
SNY
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
February 28, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
February 24, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
GMAB
SGEN
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
February 14, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
February 09, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
February 03, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
February 01, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
January 18, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
January 18, 2022
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Present at the J.P. Morgan Healthcare Conference
December 20, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
December 17, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
December 12, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
December 08, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
November 09, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
November 04, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Reports Third Quarter 2021 Financial Results
October 28, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
October 12, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
October 07, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
September 28, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
September 27, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
September 20, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
September 20, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
September 19, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
GMAB
SGEN
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 09, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
September 08, 2021
From
Seagen Inc.
Via
Business Wire
Tickers
SGEN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.